On September 20, 2022, the Board of Directors of Fresh Tracks Therapeutics, Inc. (the “Company”) appointed Deepak Chadha, the Company's Chief Research and Development Officer, to the additional position of Chief Operating Officer, resulting in Mr. Chadha holding both positions. Andrew D. Sklawer, the Company's President and Chief Operating Officer, will remain the President of the Company. No compensation adjustments were made in connection with these officer position changes.

Mr. Chadha, age 52, joined then Brickell Biotech, Inc. in 2016 and has served as the Company's Chief Research and Development Officer since 2018 and served as its Chief Regulatory, Pre-clinical, and Quality Compliance Officer from 2016 to 2018.